INNOVENT NEWS

Jan 3rd, 2025

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China’s National Medical Products Administration

More

Jan 2nd, 2025

Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate

More

Dec 20th, 2024

Innovent Receives Approval of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China’s National Medical Products Administration

More
INNOVENT ACADEMY
Innovent Academy is our signature research platform,
where world-class scientists discover new drugs,
pioneer first-in-class innovations and develop life-changing medicines.
13 Years of scientific leadership
37 Drug candidates
13 Approved products in China
PIPELINE